- Home
- CGEM vs LZM Comparison
CGEM vs LZM Comparison
Compare CGEM & LZM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEM
- LZM
- Stock Information
- Founded
- CGEM 2016
- LZM 2021
- Country
- CGEM United States
- LZM Isle of Man
- Employees
- CGEM N/A
- LZM N/A
- Industry
- CGEM Biotechnology: Pharmaceutical Preparations
- LZM Metal Mining
- Sector
- CGEM Health Care
- LZM Basic Materials
- Exchange
- CGEM Nasdaq
- LZM Nasdaq
- Market Cap
- CGEM 506.1M
- LZM N/A
- IPO Year
- CGEM 2021
- LZM N/A
- Fundamental
- Price
- CGEM $7.51
- LZM $4.18
- Analyst Decision
- CGEM Strong Buy
- LZM Strong Buy
- Analyst Count
- CGEM 8
- LZM 2
- Target Price
- CGEM $32.86
- LZM $12.50
- AVG Volume (30 Days)
- CGEM 400.4K
- LZM 116.9K
- Earning Date
- CGEM 05-14-2025
- LZM 05-12-2025
- Dividend Yield
- CGEM N/A
- LZM N/A
- EPS Growth
- CGEM N/A
- LZM N/A
- EPS
- CGEM N/A
- LZM N/A
- Revenue
- CGEM N/A
- LZM $1,020,728.00
- Revenue This Year
- CGEM N/A
- LZM N/A
- Revenue Next Year
- CGEM $278.37
- LZM $890.00
- P/E Ratio
- CGEM N/A
- LZM N/A
- Revenue Growth
- CGEM N/A
- LZM N/A
- 52 Week Low
- CGEM $7.30
- LZM $4.18
- 52 Week High
- CGEM $30.19
- LZM $9.51
- Technical
- Relative Strength Index (RSI)
- CGEM 31.21
- LZM 31.27
- Support Level
- CGEM $8.01
- LZM $4.23
- Resistance Level
- CGEM $9.16
- LZM $4.65
- Average True Range (ATR)
- CGEM 0.46
- LZM 0.23
- MACD
- CGEM -0.04
- LZM 0.03
- Stochastic Oscillator
- CGEM 9.62
- LZM 0.00
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.